Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013. In this role she was responsible for the successful launch of Kyprolis in the US and led the development of Onyx's commercial capabilities in ex-U.S. markets and in particular, in Europe. She also oversaw the development and commercial collaboration with Bayer on Nexavar® and Stivarga®.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Bone Health Business Unit from 2009 to 2011 and the U.S. Nephrology Business Unit from 2003 to 2009. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland.

She received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P). Dr. Torley is a member of the board of directors for Quest Diagnostics. She is also a former member of the Health Section Governing Board of BIO, the Biotechnology Innovation Organization.

Elaine Sun , , , Senior Vice President, Chief Financial Officer

Ms. Sun brings to Halozyme more than 20 years of experience in investment banking and life science industries. Ms. Sun joined Halozyme in March 2020 as Senior Vice President, Chief Financial Officer. She is responsible for the Finance, Information Technology and Site Operations organizations.

Prior to Halozyme, Ms. Sun served as Chief Financial Officer and Chief Strategy Officer for SutroVax, Inc., a private biopharmaceutical company, where she provided strategic, operational and financial leadership for the organization. Previously, Ms. Sun served as Managing Director and Head of West Coast Healthcare for Evercore Partners, a global independent investment banking advisory firm, and Managing Director at Merrill Lynch & Co., Inc.

Ms. Sun received her B.A. from Wellesley College and her M.B.A. from Harvard Business School. She is a member of the board of directors for Cirius Therapeutics.

Mas Matsuda , , Esq. , , Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Matsuda brings to Halozyme 20 years of corporate legal experience in the global life sciences industry. He brings corporate law, compliance, commercial law, employment and mergers and acquisitions experience, with extensive experience in the biotechnology space. Mr. Matsuda joined Halozyme in August 2018 as Vice President, Associate General Counsel and Chief Compliance Officer.  Prior to Halozyme, he served as Vice President, Law, Global Commercial Operations at Amgen, primarily responsible for strategic commercial legal support to the U.S. Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing and Biosimilars division. Throughout his 18-year career at Amgen, he held roles of increasing responsibility, including regional general counsel for the Latin America, Canada, Australia and New Zealand region, lead counsel to the European commercial operations, employment and tax groups, and lead counsel to each of the U.S. Value & Access Business Unit, Inflammation Business Unit and Nephrology Business Unit. Prior to Amgen, Mr. Matsuda worked in private practice at the law firms of Pillsbury Winthrop Shaw Pittman LLC and Orrick Herrington & Sutcliffe LLP in their respective company practice and corporate securities groups.

Mr. Matsuda received his B.S. in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and his J.D. from University of California, Hastings College of the Law.

Michael J. LaBarre , , Ph.D. , , Senior Vice President, Chief Technical Officer

Dr. LaBarre brings to Halozyme more than 25 years of experience across all aspects of biopharmaceutical research and drug development, including strong expertise in chemistry, manufacturing, and controls (CMC), regulatory strategy and product development. Dr. LaBarre joined Halozyme in 2008 and has held leadership positions in product development, alliance management, research, and regulatory affairs during that time. He is currently responsible for providing scientific and technical leadership across all Halozyme programs and is the lead expert on Halozyme’s ENHANZE® drug delivery technology.

Prior to Halozyme, Dr. LaBarre served as Vice President of Product Development at Paramount BioSciences, LLC, where he led CMC and research efforts for the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served from 1995 to 2006 in various research and development positions at Biogen Idec (formerly IDEC before the merger with Biogen in 2004), where he supported numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. and he began his career at Hybritech in San Diego in 1992. Dr. LaBarre also taught chemistry laboratory for several years as an adjunct professor at Mesa Community College early in his career.

Dr. LaBarre received his B.S. in Chemistry from Southampton College of Long Island University and his Ph.D. in Chemistry from the University of Arizona.

Fionnuala (Finn) Doyle , , , Senior VP, General Manager – ENHANZE®

Ms. Doyle brings an entrepreneurial mindset with a deep understanding of large pharma that spans more than 20 years of experience. Ms. Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms. Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme.

Prior to Halozyme, Ms. Doyle served as Senior Vice President of all Regions and Commercial for Biocon where she oversaw Biocon Biologics’ biosimilars business and reported to the Chief Executive Officer of Biocon Biologics. Throughout her 15-year career at Novartis Ms. Doyle held many leadership roles most recently as a VP, Global head Healthcare systems in the US and prior to that Country leadership roles as GM in Canada as well as in countries in Eastern and Western Europe. Ms. Doyle started her career in Novartis heading up the Neuroscience franchise before migrating to Oncology. Prior to Novartis Ms. Doyle held positions at Abbott, and other pharma companies and in MIT.

Ms. Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did post graduate research at MIT/Harvard.

Christopher Bryant , , Ph.D. , , Senior Vice President, Technical Operations & Chief Manufacturing Officer

Dr. Bryant brings strong expertise in chemistry, manufacturing, and controls (CMC), pharmaceutical and combination product development, quality assurance and regulatory strategy with more than 30 years of experience in the research, development and approval of numerous marketed therapeutics. Dr. Bryant joined Halozyme in 2021 and is responsible for providing CMC leadership across all aspects of Halozyme programs.

Prior to Halozyme, Dr. Bryant served as Vice President of Technical Operations at Levo Therapeutics, Inc., where he was responsible for the development of drug substance and drug product CMC strategies. Prior to joining Levo, Dr. Bryant held similar positions in several private biotechnology start-ups. From 2009 to 2013 Dr. Bryant served as Chief Scientific Officer for Fresenius Kabi, USA overseeing the development of a broad range of complex injectable generic medicines. From 2003 until 2009 Dr. Bryant served as Chief Operating Officer in the development efforts for the plasma protein business at Prometic Biotherapeutics. Prior to joining Prometic, Dr. Bryant served in various research and development roles from 1993 to 2003 at Aventis Behring (now CSL Behring), where he supported numerous IND and BLA submissions as well as post-market life-cycle management efforts for MONOCLATE®, MONONINE® and ZEMAIRA ®.

Dr. Bryant received his B.A. in Chemistry from the University of Northern Iowa and his Ph.D. in Chemistry from the University of California, San Diego.

Al Kildani , , , Vice President of Investor Relations and Corporate Communications

Mr. Kildani brings to Halozyme a unique perspective based on his diverse experience from both the financial and life sciences industries. Mr. Kildani joined Halozyme in November 2018 as Vice President of Investor Relations and Corporate Communications. He is responsible for developing and executing Halozyme’s investor relations strategy and serves as the primary contact for analysts and the investment community. Additionally, he oversees all aspects of corporate communications, including public relations and external and internal communications.

Prior to Halozyme, Mr. Kildani served as Vice President, Investor Relations and Business Development for Vital Therapies, Inc., where he was responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities. He previously held senior investor relations and corporate communications roles at Hologic, Inc. and Gen-Probe, Inc. Prior to these roles, Mr. Kildani spent over 12 years in the securities industry with a focus on life sciences companies. He was an analyst with Stark Investments, C.E. Unterberg, Towbin, and Pacific Growth Equities LLC.

Mr. Kildani received his B.S. in Business Administration from Boston College, and is a member of the National Investor Relations Institute (NIRI).

Amy Fox , , , Vice President of Human Resources

Ms. Fox has more than 20 years of human resources experience and expertise in helping leaders build high-performing, agile organizations. She joined Halozyme in January 2020 as Vice President of Human Resources and is responsible for all aspects of Human Resources.

Prior to Halozyme, Ms. Fox served as Vice President, Human Resources for Evolus, Inc., where she was responsible for the overall talent strategy leading initiatives focused on building a strong culture, organizational development, people development, talent acquisition and compensation and benefits. Prior to joining Evolus, she served as Vice President of Human Resources and HR Business Partner at Orexigen Therapeutics, Inc., where she worked closely with the U.S. Commercial organization. Prior to these roles, Ms. Fox spent more than 15 years in a variety of human resources roles spanning the life sciences, legal, publishing and professional services industries.

Ms. Fox received her B.A. from University of California, San Diego.

Renee Tannenbaum , , BSc, PharmD, MBA , , Vice President, Global Partnering

Dr. Tannenbaum has more than 30 years of operating and general management experience in the biopharmaceutical industry, including broad global drug development and commercialization experience. Dr. Tannenbaum joined Halozyme in August 2016 as Vice President, Global Alliance Management. She is responsible for the overall relationship and program execution for the company’s strategic alliances with the ENHANZE® drug delivery technology. In addition, she also oversees the company’s business development activities.

Prior to joining Halozyme, Dr. Tannenbaum held several senior roles, including Head of Global Customer Excellence at AbbVie, Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., Head of Global Commercial Operations at Novartis AG and Vice President of ConVaTec Americas, a Bristol-Myers Squibb corporation.

Dr. Tannenbaum received her MBA from Temple University School of Business, her Pharm.D. at the Philadelphia College of Pharmacy and Sciences, and her B.Sc. degree from the University of Connecticut School of Pharmacy. She currently serves as Adjunct Professor at the University of the Sciences at Philadelphia and serves on the Board of Directors at Zogenix, Inc.

Steve Knowles , , MB.BS, M.R.C.P., M.F.P.M. , , Chief Medical Officer

Dr. Knowles has deep pharmacovigilance and medical affairs experience gained over a career spanning almost 20 years. Dr. Knowles joined Halozyme in January 2018 as Vice President, Drug Safety & Pharmacovigilance. He is responsible for the Medical, Regulatory and Drug Safety organizations.

Prior to Halozyme, Dr. Knowles served as Senior Medical Director, Global Patient Safety and Benefit Risk Management at Eli Lilly & Co. where he led the global safety physician/scientist group responsible for overseeing the safety profiles and benefit risk management of medicines across all therapeutic areas and phases of development and supported numerous BLA and MAA submissions. During his 16 years at Lilly, he held positions in Medical Affairs and from 2005 to 2017 he held roles of increasing responsibility within Global Patient Safety. Prior to these roles, Dr. Knowles spent more than 17 years in clinical practice in the UK in both hospital-based and general practice roles.

Dr. Knowles received his Bachelor of Medicine and Surgery degrees (MB.BS) from the University of Newcastle Upon Tyne and is a Member of the Royal College of Physicians (MRCP) and a Member of the Faculty of Pharmaceutical Medicine (MFPM).

Todd Butler , , , Chief of Staff to the CEO, Vice President, Head of Project Management

Mr. Butler has more than 25 years of drug development and leadership experience in the biopharmaceutical industry. Mr. Butler joined Halozyme in November 2017 as Vice President, Clinical Development Operations. In this role he was accountable for the successful execution and conduct of all Halozyme global oncology studies, including data quality and readiness for data analysis.

In November 2019 he assumed the role of Chief of Staff to the CEO, Vice President, Head of Project Management with accountability to oversee overall operational effectiveness. Prior to Halozyme, Mr. Butler served as Executive Director of Clinical Operations at MEI Pharma, Inc., an oncology-based clinical development pharmaceutical company, where he led the efforts of the execution of global clinical trials. Prior to joining MEI Pharma, Mr. Butler held positions of increasing responsibility and leadership at other various biopharmaceutical companies, including Prometheus Laboratories (a Nestlé Health Science subsidiary), Shire Pharmaceutical, Inc., Pfizer, Inc., and Otsuka America Pharmaceutical, Inc. Mr. Butler also held the position of Regional Director at Covance, Inc., a global Clinical Research Organization (CRO) where he provided strategic and tactical planning across the company’s multiple Clinical Research units.

Mr. Butler received his B.S. in Biology from Butler University and certification in a leadership program through the Center for Management Development at London Business School.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.